Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Glaukos is a strong investment opportunity based on their impressive pipeline and potential for long-term growth. With consistently strong revenue growth and a robust portfolio of products, Glaukos is well-positioned to maintain core market share and see strong contributions from new products such as iDose and Epioxa. Additionally, their innovative approach to ophthalmic treatments and partnerships with major players in the medical industry further solidify their potential for future success.

Bears say

Glaukos is experiencing strong revenue growth and is making investments in their pipeline. However, there are four key risks that may impact their success: sales execution, competition in the MIGS market, reimbursement obstacles, and slow market adoption of their Corneal Health products. Despite positive gross and operating margins, there is still potential for challenges in market access and continued competition in the ophthalmic medical technology and pharmaceutical industry.

Glaukos (GKOS) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Glaukos (GKOS) has a Strong Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $139.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $139.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.